Table of Contents (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40674 MaxCyte, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...

MaxCyte, Inc. (NASDAQ:MXCT) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Sean Menarguez - Director of Investor Relations Douglas Doerfler - Founder, President & Chief Executive Officer Ronald Holtz - Interim Chief Financial Officer Conference Call Participants Julie Simmonds - Panmure Gordon Madeline Mollman - William Blair Daniel Arias - Stifel Max Masucci - Cowen and Company Hannah Hefley - Stephens Inc. Vidyun Bais - BTIG Operator Good day, ladies and gentlemen, and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 52-2210438 (Sta ...

Call Start: 16:30 January 1, 0000 5:07 PM ET MaxCyte, Inc. (NASDAQ:MXCT) Q2 2022 Earnings Conference Call August 10, 2022 16:30 ET Company Participants Sean Menarguez - Director of Investor Relations Doug Doerfler - Founder, President & Chief Executive Officer Ron Holtz - Chief Financial Officer Conference Call Participants Max Masucci - Cowen Julie Simmonds - Panmure Dan Arias - Stifel Operator Good day and thank you for standing by and welcome to MaxCyte Second Quarter 2022 Earnings Conference Call. [Oper ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) (Exact name of registrant as specified in its charter) Delaware 52-2210438 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 9713 Key West Avenue, Suite 400 Rockville, Maryland 20850 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT T ...

M MaxCyte® Driving the Next Generation of Cell-Based Therapies MaxCyte Corporate Presentation NASDAQ: MXCT • LSE: MXCT May, 9 2022 are trademarks of MaxCyte, Inc. in the U.S.A. ® ® ® ® TM © 2019 MaxCyte, Inc. All Rights Reserved info@maxcyte.com | www.maxcyte.com ir@maxcyte.com | www.maxcyte.com Disclaimer The content of this document (the "Presentation") has not been approved by an authorized person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"), as amended. Reliance on this doc ...

MaxCyte, Inc. (NASDAQ:MXCT) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Doug Doerfler – President and Chief Executive Officer Amanda Murphy – Chief Financial Officer Sean Menarguez – Investor Relations Conference Call Participants Stephanie Iannetta – Cowen and Company Matthew Larew – William Blair Mark Belford – Stephens Inc. Vidyun Bais – BTIG Operator Good day and thanks for standing by. Operator Good day and thank you for standing by. Welcome tot he MaxCyte First Quarter ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

MaxCyte, Inc. (NASDAQ:MXCT) Q4 2021 Earnings Conference Call March 22, 2022 4:30 PM ET Company Participants Sean Menarguez - Investor Relations Doug Doerfler - President and Chief Executive Officer Amanda Murphy - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Inc. Julie Simmonds - Panmure Gordon Paul Cuddon - Numis Securities Daniel Arias - Stifel Matt Larew - William Blair Max Masucci - Cowen and Company Mark Massaro - BTIG Operator Thank you for standing by. And welcome to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...